ÂÜÀòÂÒÂ×

Fiona MacLaughlin currently serves as a Non Executive Director at Asgard Therapeutics, Nucleome Therapeutics, AviadoBio, Mestag Therapeutics, Pulmocide, and Astraveus, with a notable previous role at Calypso Biotech, which was acquired by Novartis. Fiona MacLaughlin is also a Senior Director at Johnson & Johnson Innovation JJDC Inc, leading investments in the EMEA region with a focus on pharmaceuticals. Previous directorships include Syndesi Therapeutics, which was acquired by AbbVie, and a position as an Advisory Board member at Apollo Therapeutics. Fiona MacLaughlin holds a PhD in Pharmaceutics/Drug Delivery and a BPharm in Pharmacy, both from the University of Nottingham.